B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma without mediastinal disease: mimicking nodular sclerosis classical Hodgkin lymphoma

被引:0
作者
Noriko Iwaki
Yasuharu Sato
Toshiro Kurokawa
Yoshinobu Maeda
Kyotaro Ohno
Mai Takeuchi
Katsuyoshi Takata
Yorihisa Orita
Shinji Nakao
Tadashi Yoshino
机构
[1] Okayama University Graduate School of Medicine,Department of Pathology
[2] Dentistry and Pharmaceutical Sciences,Cellular Transplantation Biology
[3] Kanazawa University Graduate School of Medical Science,Department of Hematology
[4] Toyama Red Cross Hospital,Department of Pathology
[5] Toyama Red Cross Hospital,Otolaryngology Head and Neck Surgery
[6] Okayama University Graduate School of Medicine,undefined
[7] Dentistry and Pharmaceutical Sciences,undefined
来源
Medical Molecular Morphology | 2013年 / 46卷
关键词
Gray-zone lymphoma; Diffuse large B-cell lymphoma; Nodular sclerosis classical Hodgkin lymphoma; Immunohistochemistry;
D O I
暂无
中图分类号
学科分类号
摘要
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma (BCLu-DLBCL/CHL), also known as gray-zone lymphoma, has overlapping clinical and biological characteristics of both diffuse large B-cell lymphoma and classical Hodgkin lymphoma (CHL). These lymphomas are typically associated with mediastinal disease, and extranodal involvement is rare. In the present report, we describe a case of a 78-year-old woman with BCLu-DLBCL/CHL found to have extranodal lesions and no evidence of mediastinal disease. Although biopsy specimens were histologically similar to nodular sclerosis CHL, the tumor cells were positive for CD30 and mature B-cell markers, such as CD20, CD79a, PAX5, BOB.1, and OCT-2, but negative for CD15. Furthermore, the patient had extranodal lesions and an increased level of soluble IL-2 receptor. These findings are unusual in CHL. Therefore, we diagnosed the patient with BCLu-DLBCL/CHL. She received adriamycin, bleomycin, vincristine, and dacarbazine therapy and exhibited partial response. Some cases without mediastinal disease, such as our case, have been reported; however, these cases are rare and further studies are required.
引用
收藏
页码:172 / 176
页数:4
相关论文
共 166 条
[1]  
Traverse-Glehen A(2005)Mediastinal gray zone lymphoma: the missing link between classic Hodgkin’s lymphoma and mediastinal large B-cell lymphoma Am J Surg Pathol 29 1411-1421
[2]  
Pittaluga S(2005)Large B-cell lymphoma with Hodgkin’s features Histopathology 47 101-110
[3]  
Gaulard P(2011)Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do? Curr Hematol Malig Rep 6 157-163
[4]  
Sorbara L(2012)The spectrum of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a description of 10 cases Mod Pathol 25 661-674
[5]  
Alonso MA(2011)Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations Mod Pathol 24 1586-1597
[6]  
Raffeld M(2010)Two cases of mediastinal gray zone lymphoma J Clin Exp Hematop 50 143-149
[7]  
Jaffe ES(2010)Phase II study of ABVd therapy for newly diagnosed clinical stage II–IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305) Int J Hematol 92 713-724
[8]  
Garcia JF(2003)The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma Blood 102 3871-3879
[9]  
Mollejo M(2003)Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma J Exp Med 198 851-862
[10]  
Fraga M(2003)The B-cell transcription factors BSAP, OCT-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma Am J Clin Pathol 120 767-777